ELITE: Early Versus Late Intervention Trial With Estradiol
Completed
National Institute on Aging (NIA)
Phase 2/Phase 3
2004-07-01
The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the
progression of early (subclinical) atherosclerosis and cognitive decline in healthy
postmenopausal women.
ELITE: Early Versus Late Intervention Trial With Estradiol
Completed
University of Southern California
Phase 2/Phase 3
2004-07-01
The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the
progression of early (subclinical) atherosclerosis and cognitive decline in healthy
postmenopausal women.
EPAT: Estrogen in the Prevention of Atherosclerosis Trial
Completed
Mead Johnson Nutrition
Phase 2/Phase 3
1994-04-01
The purpose of this study is to determine the effects of estrogen replacement therapy (ERT)
on the progression of early atherosclerosis in healthy postmenopausal women without
preexisting cardiovascular disease (CVD).
EPAT: Estrogen in the Prevention of Atherosclerosis Trial
Completed
National Institute on Aging (NIA)
Phase 2/Phase 3
1994-04-01
The purpose of this study is to determine the effects of estrogen replacement therapy (ERT)
on the progression of early atherosclerosis in healthy postmenopausal women without
preexisting cardiovascular disease (CVD).
Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms
Completed
Pfizer
N/A
2007-04-01
The purpose of this study is to determine if long acting tolterodine confers more benefit
than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12
weeks post-treatment initiation. The hypothesis is that low dose intra-vaginal estrogen
confers greater benefit than tolterodine in the treatment of Overactive Bladder symptoms.
Secondary outcomes were to assess if the addition of the other therapy to the treatment
regimen conferred benefit at 24 weeks and 52 weeks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
